Share Capital Increase Registered
Press
4 Jul
Written By Aliisa Paulus
EXACT Therapeutics AS - Share Capital Increase Registered

OSLO/LONDON, 4th July 2022: Reference is made to the announcement by EXACT Therapeutics AS ('EXACT-Tx' or the 'Company') on 9 June 2022 regarding the issuance of 5,052 new shares in the Company, for the purpose of issuing shares under the Company's restricted stock unit (RSU) program to its Board members.

The share capital increase pertaining to the issuance of the new shares has now been registered with the Norwegian Register of Business Enterprises. The Company's new registered share capital is NOK 119,988.876 divided into 29,997,219 shares, each with a nominal value of NOK 0.004.

DISCLOSURE REGULATION This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

ENDS

For more information, please contact:

Per Walday, CEO
 EXACT Therapeutics
Email: per.walday@exact-tx.com

Dominic Moreland, CFO
 EXACT Therapeutics
Email: Dominic@exact-tx.com

About EXACT-Tx
 EXACT-Tx is a Norwegian clinical-stage precision health company developing a technology platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®). ACT® is a proprietary formulation of microclusters (PS101) activated by ultrasound for enhanced drug targeting deployed in multiple indications to enhance the therapeutic efficacy of medicines through the use of ultrasound-mediated drug delivery, for patients across multiple diseases. www.exact-tx.com

Forward looking statements
 This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by this forward-looking statement.

Aliisa Paulus

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Exact Therapeutics ASA published this content on 05 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 September 2022 21:29:05 UTC.